Results 71 to 80 of about 3,654 (190)

Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022–June 2023

Journal of Viral Hepatitis, Volume 33, Issue 1, January 2026.
ABSTRACT Pakistan has the world's highest hepatitis C virus (HCV) prevalence, yet access to HCV care remains limited. In collaboration with the Ministry of Health Sindh, Médecins Sans Frontières implemented a simplified, decentralised model for HCV screening and treatment at a government‐run primary health centre (PHC) in Baldia Town, Karachi, Pakistan.
Sara Mazzilli, Muhammad K. Aslam, Mubashir Ahmed, Yves Wailly, Marta Miazek, Sana Ashraf, Ashok Ravji, William A. de Glanville, Petros Isaakidis   +8 more
wiley   +1 more source

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study

Infectious Diseases and Therapy, 2020
Introduction Clinical trials of direct-acting antivirals for patients with decompensated cirrhosis have been conducted, but there is limited information on the medicinal applications in clinical settings.
Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Makoto Nakamuta, Koichi Takaguchi, Tsunamasa Watanabe, Atsushi Hiraoka, Haruki Uojima, Toru Ishikawa, Motoh Iwasa, Toshifumi Tada, Akito Nozaki, Makoto Chuma, Shinya Fukunishi, Akira Asai, Toru Asano, Chikara Ogawa, Hiroshi Abe, Naoki Hotta, Toshihide Shima, Etsuko Iio, Shigeru Mikami, Yoshihiko Tachi, Shinichi Fujioka, Hironao Okubo, Noritomo Shimada, Joji Tani, Isao Hidaka, Akio Moriya, Kunihiko Tsuji, Takehiro Akahane, Naoki Yamashita, Tomomi Okubo, Taeang Arai, Kiyoshi Morita, Kazuhito Kawata, Yasuhito Tanaka, Takeshi Okanoue, Shin Maeda, Takashi Kumada, Katsuhiko Iwakiri, KTK49 Liver Study Group   +42 more
doaj   +1 more source

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C

International Journal of Hepatology, Volume 2026, Issue 1, 2026.
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Seiichi Tawara, Asuka Watanabe, Junya Yamaguchi, Mai Omi, Tetsuro Miyazaki, Haruka Taguchi, Ryosuke Kiyota, Takuo Yamai, Shoichiro Kawai, Takuya Inoue, Takayuki Yakushijin, Dirk Uhlmann   +11 more
wiley   +1 more source

HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models

, 2018
BACKGROUND & AIMS: Chronic liver diseases caused by hepatitis C virus (HCV) genotype 6 are prevalent in Asia, and millions of people require treatment with direct-acting antiviral regimens, such as NS5A inhibitor velpatasvir combined with the NS5B ...
Pham, Long, Jannie Pedersen, Yi-Ping Li, Ramirez Almeida, Santseharay, Li, Yiping, Pedersen, Jannie, Long V. Pham, Ulrik Fahnøe, Judith M. Gottwein, Fahnøe, Ulrik, Santseharay Ramirez, Bukh, Jens, Jens Bukh, Gottwein, Judith Margarete   +13 more
core   +1 more source

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: A meta-analysis

, 2019
Background and aims: In literature systematic data on treatment with the fixed-dose combination of sofosbuvir and velpatasvir for 12 weeks in anti-HCV/HCV RNA positive subjects with mild fibrosis and naïve to previous Interferon free regimen are scanty.
Coppola N., Pisaturo M., Onorato L., Russo A.   +3 more
core   +1 more source

Development And Validation of New RP-HPLC Method For the Simultaneous Estimation of Sofosbuvir And Velpatasvir In Combined Pharmaceutical Dosage Form

, 2023
A simple, rapid, accurate, precise, specific and sensitive reverse phase-HPLC method has been developed and validated for the simultaneous estimation of Sofosbuvir and Velpatasvir in bulk and pharmaceutical dosage form. The chromatographic separation was
P. Seetharamaiah*, Nagaraju Pappula, JVLN. Seshagiri Rao and D. Gowrisankar
core   +1 more source

Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan

The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 11, November 2025.
ABSTRACT This study examines the impact of hepatitis C virus (HCV) eradication through sofosbuvir/velpatasvir (SOF/VEL) treatment on glycated hemoglobin (HbA1c) levels in patients with chronic hepatitis C and type 2 diabetes mellitus (T2DM). Utilizing data from the Taiwan HCV Registry, a retrospective analysis was conducted on 2180 patients who met the
Szu‐Jen Wang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Jong Bair, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yuan Hsieh, Tzong‐Hsi Lee, Pei‐Lun Lee, Wen‐Chih Wu, Chih‐Lin Lin, Wei‐Wen Su, Sheng‐Shun Yang, Chia‐Chi Wang, Jui‐Ting Hu, Lein‐Ray Mo, Chun‐Ting Chen, Yi‐Hsiang Huang, Chun‐Chao Chang, Chia‐Sheng Huang, Guei‐Ying Chen, Chien‐Neng Kao, Chi‐Ming Tai, Chun‐Jen Liu, Mei‐Hsuan Lee, Pei‐Chien Tsai, Shu‐Chi Wang, Chia‐Yen Dai, Jia‐Horng Kao, Han‐Chieh Lin, Wang‐Long Chuang, Kuo‐Chih Tseng, Chi‐Yi Chen, Chung‐Feng Huang, Ming‐Lung Yu   +43 more
wiley   +1 more source

High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam

Journal of Viral Hepatitis, Volume 32, Issue 11, November 2025.
ABSTRACT People who inject drugs (PWID) are highly affected by hepatitis C (HCV) worldwide, particularly in low‐ and middle‐income countries (LMICs), where access to addiction services is often limited. Reducing the burden of HCV, as promoted by WHO, requires effective interventions in this high‐risk population.
Didier Laureillard, Nguyen Thanh Binh, Vu Hai Vinh, Tran Thi Hong, Catherine Quillet, Nham Thi Tuyet Thanh, Roselyne Vallo, Bach Thi Nhu Quynh, Jean Pierre Moles, Khuat Thi Hai Oanh, Duong Thi Huong, Delphine Rapoud, Jonathan Feelemyer, Laurent Michel, Peter Vickerman, Hannah Fraser, Laurence Weiss, Maud Lemoine, Karine Lacombe, Don Des Jarlais, Pham Minh Khue, Nicolas Nagot   +21 more
wiley   +1 more source

Drug Repurposing of Approved Drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19

, 2020
Pneumonia of unknown cause detected in Wuhan, China was first reported to the WHO Country Office in China on 31 December 2019. The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020.
Nilam, Vaghamshi, Himani, Gandhi, Urvisha, Beladiya, Pravin, Dudhagara, Vishal, Mevada, Rajesh, Patel   +5 more
core   +1 more source

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection [PDF]

The Korean Journal of Internal Medicine, 2023
Hyun Phil Shin
doaj   +1 more source